Oncology News | pharmaphorum

News

Merck's Welireg becomes first drug for rare VHL tumours in U...

Merck & Co has extended its range of cancer medicines in the US after claiming FDA approval for Welireg – a drug it acquired as part of its $2.2 billion takeover of Peloton Therapeutics

News

FDA starts speedy review of Keytruda for adjuvant kidney can...

Merck & Co is looking at a decision from the FDA in December on its application to market Keytruda as a post-surgery treatment for people with kidney cancer, after a priority review.

News

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo

News

Armed with phase 3 data, Roche preps filing for Polivy in fi...

Roche has the results it was hoping for in a phase 3 trial of Polivy in newly diagnosed diffuse large B-cell lymphoma (DLBCL) – an indication it thinks could be worth up to $2 billion.

News

Sanofi and Regeneron eye Libtayo challenge to Keytruda in fi...

Sanofi and Regeneron's latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe conte

News

Failed trial nixes another FDA approval, this time for BMS' ...

Bristol-Myers Squibb's HDAC inhibitor Istodax has been on the US market for a decade as a treatment for peripheral T-cell lymphoma (PTCL), but will now be withdrawn from sale after a failed

Merck's Welireg becomes first drug for rare VHL tumours in U...

FDA starts speedy review of Keytruda for adjuvant kidney can...

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

Armed with phase 3 data, Roche preps filing for Polivy in fi...

Sanofi and Regeneron eye Libtayo challenge to Keytruda in fi...

Failed trial nixes another FDA approval, this time for BMS' ...

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks